-
Product Insights
Myasthenia Gravis Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update
Myasthenia gravis is autoimmune neuromuscular disease characterized by weakness and rapid fatigue of any of the muscles under voluntary control. Symptoms include drooping of one or both eyelids, diplopia and difficulty swallowing, chewing and speaking. Treatment includes immunosuppressants, corticosteroids and surgery. The Myasthenia Gravis - Drugs In Development research report provides a comprehensive overview on the therapeutics under development for Myasthenia Gravis, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and...
-
Sector Analysis
Competitor Landscape: Rheumatoid Arthritis
Sociable Pharma’s ‘Treatment Landscape’ contains evaluations of ongoing development activities within the Rheumatoid Arthritis (RA) market, analysis of current & potential future product positioning, and forecast approval dates (by quarter) for candidates in Phase II development, or higher
-
Sector Analysis
Competitor Landscape: Spondyloarthritis
Sociable Pharma’s ‘Treatment Landscape’ contains evaluations of ongoing development activities within the spondyloarthritis (SpA) market, analysis of current & potential future product positioning, and forecast approval dates (by quarter) for candidates in Phase II development, or higher
-
Product Insights
Thrombocytopenia Global Clinical Trials Review, H2, 2018
GlobalData's clinical trial report, “Thrombocytopenia Global Clinical Trials Review, H2, 2018" provides an overview of Thrombocytopenia clinical trials scenario. This report provides top line data relating to the clinical trials on Thrombocytopenia. Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. Report also provides prominent drugs for in-progress...
-
Sector Analysis
OpportunityAnalyzer: Immune Thrombocytopenia (ITP) – Opportunity Analysis and Forecasts to 2025
Immune Thrombocytopenia (ITP) is an auto-immune-related bleeding disorder characterized by a low platelet count. Patients with severe ITP often experience fatigue, bruising, and reduced quality of life. Although most ITP cases are not fatal, approximately 3% of chronic refractory ITP patients die of complications, such as intracranial hemorrhage and infection. Most of the ITP treatments available are off-label drugs. In 2008, a class of new drug, the thrombopoietin receptor agonists (TRAs), was approved and revolutionized the treatment of ITP. GlobalData...